Study of Comparative Bioavailability and Pharmacokinetics of ACM-001.1) and Pindolol in Healthy Volunteers (HV)
Study Details
Study Description
Brief Summary
The aim of this early phase two-part study was to compare the bioavailability (BA) pharmacokinetics (PK) and pharmacodynamics (PD) of racemic pindolol with the benzoate salt of the S-enantiomer of pindolol (ACM-001.1) and provide safety information. A total of 51 healthy male and female subjects were enrolled, and 48 healthy subjects completed the study.
Part 1 consisted of two Groups to compare BA and PK, Group 1 received two treatment sequences of a single dose of ACM-001.1 versus racemic pindolol; Group 2 ran in parallel with Group 1 and assessed the PK of a single dose of racemic pindolol in a single period.
Part 2 consisted of four groups, to evaluate the steady state PK and PD of ACM-001.1 with multiple ascending doses over 4 days.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Part 1 Group1 (AB) Part 1 Group1 Subjects were randomised to two treatment regimens (A and B) and received treatment sequence AB in a 2-period cross over. Regimen A = 15 mg ACM-001.1 and matching placebo. Regimen B = 30 mg pindolol. |
Drug: Part 1 Group 1 (ACM-001.1and Pindolol and Placebo)
Drug: ACM-001.1 immediate release tablets for oral use and matching placebo, and pindolol tablets for oral use.
Subjects randomised to Regimen A received placebo tablets to match the tablet number received by subjects in Regimen B.
|
| Experimental: Part 1 Group 1 (BA) Subjects were randomised to two treatment regimens (A and B) and received treatment sequence BA in a 2-period cross over. Regimen B = 30 mg pindolol. Regimen A = 15 mg ACM-001.1 and matching placebo. |
Drug: Part 1 Group 1 (ACM-001.1and Pindolol and Placebo)
Drug: ACM-001.1 immediate release tablets for oral use and matching placebo, and pindolol tablets for oral use.
Subjects randomised to Regimen A received placebo tablets to match the tablet number received by subjects in Regimen B.
|
| Experimental: Part 1 Group 2 (C) Subjects were non-randomised; received regimen C in parallel with Group 1 in a single period. Regimen C = 15 mg pindolol. |
Drug: Part 1 Group 2 (Pindolol)
Drug: Pindolol tablets for oral use.
|
| Experimental: Part 2 Group D Subjects received one of the four regimens over a four day treatment period. Regimen D = 20 mg pindolol BID (bis in die) for four days. |
Drug: Part 2 Group D (Pindolol)
Drug: Pindolol tablets for oral use. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
|
| Experimental: Part 2 Group E Subjects received one of the four regimens over a four day treatment period. Regimen E = 5 mg ACM-001.1 and placebo BID for four days. |
Drug: Part 2 Group E (ACM-001.1 and Placebo)
Drug: ACM-001.1 immediate release tablets for oral use and matching placebo. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
|
| Experimental: Part 2 Group F Subjects received one of the four regimens over a four day treatment period. Regimen F = 10 mg ACM-001.1 and placebo BID for four days. |
Drug: Part 2 Group F (ACM-001.1 and Placebo)
Drug: ACM-001.1 immediate release tablets for oral use and matching placebo. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
|
| Experimental: Part 2 Group G Subjects received one of the four regimens over a four day treatment period. Regimen G = 15 mg ACM-001.1 and placebo BID for four days. |
Drug: Part 2 Group G (ACM-001.1 and Placebo)
Drug: ACM-001.1 immediate release tablets for oral use and matching placebo. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
|
Outcome Measures
Primary Outcome Measures
- Part 1 Composite of PK parameters following single doses [Up to 5 days]
Comparative bioavailability of S- pindolol and pindolol include: area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUC[0-infinite].
- Part 1 PK parameters following single doses [Up to 5 days]
Comparative bioavailability of S- pindolol and pindolol include:maximum observed concentration (Cmax)
- Part 1 PK parameters following single doses [Up to 5 days]
Comparative bioavailability of S- pindolol and pindolol include:time of occurrence of Cmax (Tmax)
- PK parameters following single doses [Up to 5 days]
Comparative PK parameters of S- pindolol and racemic pindolol include: area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUC[0-infinite]).
- PK parameters following single doses [Up to 5 days]
Comparative PK parameters of S- pindolol and racemic pindolol include: maximum observed concentration (Cmax)
- PK parameters following single doses [Up to 5 days]
Comparative PK parameters of S- pindolol and racemic pindolol include: t time of occurrence of Cmax (Tmax)
- Stoichiometric dose relationship measured using PK parameters following single doses [Up to 5 days]
PK parameters of S- pindolol and racemic pindolol include: area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUC[0-infinite])
- Stoichiometric dose relationship measured using PK parameters following single doses [Up to 5 days]
PK parameters of S- pindolol and racemic pindolol include: maximum observed concentration (Cmax).
- Part 2 Composite of PK parameters following multiple doses in plasma [Up to 6 days]
PK parameters of S- pindolol/racemic pindolol:Area under the curve for interval between doses (tau) (AUC(0 tau);Area under the concentration-time curve from time zero (pre-dose) to last time of measurable concentration (AUC[0-t])
- Part 2 Composite of PK parameters following multiple doses in plasma [Up to 6 days]
PK parameters of S- pindolol/racemic pindolol: Maximum observed concentration (Cmax),
- Part 2 Composite of PK parameters following multiple doses in plasma [Up to 6 days]
PK parameters of S- pindolol/racemic pindolol: Time to first occurrence of Cmax from plasma concentration-time data(Tmax).
- Pharmacodynamics of ACM-001.1: Cardiovascular vital parameter- heart rate [Up to 6 days]
Heart rate (beats per minute)
- Cardiovascular vital parameter- blood pressure [Up to 6 days]
Systolic blood pressure (mmHG) and diastolic blood pressure (mmHG)
- Serum biomarker- DHEA/Cortisol [Day 1 at pre-dose. Day 4 at pre-dose, 1.5 hours]
Dehydroepiandrosterone (DHEA)/Cortisol (ng/mL). Serum concentrations were determined using validated analytical method.
- Serum biomarker- Myostatin [Day 1 at pre-dose. Day 4 at pre-dose, 1.5 hours.]
Myostatin (pg/mL).Serum concentrations were determined using validated analytical method.
- Serum biomarker- Folistatin [Day 1 at pre-dose. Day 4 at pre-dose, 1.5 hours.]
Folistatin (pg/mL).Serum concentrations were determined using validated analytical method.
- Serum biomarker-IGF1 [Day 1 at pre-dose. Day 4 at pre-dose, 1.5 hours.]
Insulin-like growth factor (IGF)1 (pg/mL).Serum concentrations were determined using validated analytical method.
- Serum biomarker - (Type 3 procollagen peptide) PIIINP [Day 1 at pre-dose. Day 4 at pre-dose, 1.5 hours.]
PIIINP (pg/mL).Serum concentrations were determined using validated analytical method.
- Serum biomarker - monokine-induced by gamma interferon (MIG/CXL9) Leptin [Day 1 at pre-dose. Day 4 at pre-dose, 1.5 hours.]
Leptin (pg/mL).Serum concentrations were determined using validated analytical method.
- Serum biomarker - epithelial neutrophil activating peptide 78 (ENA78) [Day 1 at pre-dose. Day 4 at pre-dose, 1.5 hours.]
ENA78 (pg/mL).Serum concentrations were determined using validated analytical method.
- Serum biomarker - Ghrelin [Day 1 at pre-dose. Day 4 at pre-dose, 1.5 hours.]
Ghrelin (pg/mL).Serum concentrations were determined using validated analytical method.
- Serum biomarker - Growth Hormone Receptor Hormone [Day 1 at pre-dose. Day 4 at pre-dose, 1.5 hours.]
Growth Hormone Receptor Hormone (ng/mL).Serum concentrations were determined using validated analytical method.
- Serum biomarker - Somatostatin [Day 1 at pre-dose (baseline). Day 4 at pre-dose, 1.5 hours.]
Somatostatin (pg/mL).Serum concentrations were determined using validated analytical method.
Secondary Outcome Measures
- Part 1 Composite PK parameters in urine following single doses [Up to 5 days]
PK parameters of S-pindolol, R-pindolol and pindolol: Amount excreted (Ae), Cumulative amount excreted (CumAe), Fraction of dose excreted (%Ae) and Cumulative fraction of dose excreted (%CumAe)
- Part 2 Composite PK parameters in urine following multiple doses and pindolol [Up to 7 days]
PK parameters of S-pindolol, R-pindolol and pindolol: Amount excreted (Ae), Cumulative amount excreted (CumAe), Fraction of dose excreted (%Ae) and Cumulative fraction of dose excreted (%CumAe)
- Part 1 and Part 2 Analysis of S-pindolol and R-pindolol concentrations in plasma for any in vivo conversion [Up to 4 days]
Plasma concentrations were determined using validated analytical methods.
- Part 1 Number of participants with adverse events following single doses as a measure of safety and tolerability [From screening: day -28 to follow up call day 8 (part 1), up to 36 days]
AEs will be collected from provision of written informed consent until discharge at the follow-up contact.
- Part 2 Number of participants with adverse events following single doses as a measure of safety and tolerability [From screening: day -28 to follow up call day up to 11 (part 2), up to 39 days]
AEs will be collected from provision of written informed consent until discharge at the follow-up contact
- Part 2 only - Pulmonary function test [Up to 32 days]
Forced expiratory spirometry to determine parameters FEV1, FVC, FEV1/FVC
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Healthy males or non-pregnant, non-lactating healthy females
-
Aged 20 to 45 years inclusive at the time of signing informed consent
-
Body Mass Index (BMI) of 18.0 to 30.0 kg/m2 as measured at screening
-
Weight of 50 to 100 kg at screening
Exclusion Criteria:
-
Subjects who had received any investigational medicinal product in a clinical research study within the 90 days prior to Day 1,
-
Subjects for whom pindolol was contraindicated: hypersensitivity to the active substance or to any of its listed excipients.
-
Evidence of current Severe Acute Respiratory Coronavirus 2 infection.
-
History of any drug or alcohol abuse in the past 2 years.
-
Females of childbearing potential who were pregnant or lactating.
-
History of clinically significant cardiovascular disease, Raynaud's disease or phenomenon, renal, hepatic, dermatological, chronic respiratory or gastrointestinal disease, neurological or psychiatric disorder.
-
Subjects who were found to have mean heart rate less than 50 bpm at rest or mean systolic blood pressure (BP) less than 100 mmHg or mean diastolic heart rate less than 50 mmHg.
-
Subjects who were taking, or had taken, any prescribed or over-the-counter drug or herbal remedies (other than paracetamol, hormonal replacement therapy/hormonal contraception). Pindolol should not be taken in conjunction with agents which inhibit calcium transport.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Quotient Sciences Ltd | Ruddington | United Kingdom | NG11 9JS |
Sponsors and Collaborators
- Actimed Therapeutics Ltd
- Quotient Sciences
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- ACM-2021-1-CT
- QSC205141